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We evaluated the pharmacodynamic relationships between mycophenolic acid (MPA), the active metabolite
of mycophenolate mofetil (MMF), and outcomes in 308 patients after nonmyeloablative hematopoietic cell
transplantation. Patients were conditioned with total body irradiation  ﬂudarabine, received grafts from
HLA-matched related (n ¼ 132) or unrelated (n ¼ 176) donors, and received postgrafting immunosuppression
with MMF and a calcineurin inhibitor. Total and unbound MPA pharmacokinetics were determined to day 25;
maximum a posteriori Bayesian estimators were used to estimate total MPA concentration at steady state
(Css). Rejection occurred in 9 patients, 8 of whom had a total MPA Css less than 3 mg/mL. In patients receiving
a related donor graft, MPA Css was not associated with clinical outcomes. In patients receiving an unrelated
donor graft, low total MPA Css was associated with increased grades III to IV acute graft-versus-host disease
and increased nonrelapse mortality but not with day 28 T cell chimerism, disease relapse, cytomegalovirus
reactivation, or overall survival. We conclude that higher initial oral MMF doses and subsequent targeting of
total MPA Css to greater than 2.96 mg/mL could lower grades III to IV acute graft-versus-host disease and
nonrelapse mortality in patients receiving an unrelated donor graft.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
The development of nonmyeloablative allogeneic hema-
topoietic cell transplantation (HCT) conditioning regimens
expanded the availability of this potentially curative proce-
dure to patients who cannot tolerate the toxicity of mye-
loablative conditioning due to age or comorbidity [1,2].
Postgrafting immunosuppression used with these regimens,
which aims to facilitate allogeneic engraftment and control
graft-versus-host disease (GVHD), often consists of a calci-
neurin inhibitor (CNI) and mycophenolate mofetil (MMF).
During the initial clinical trials of nonmyeloablative HCT,
oral MMF was administered every 12 hours (Q12 hr), as in
solid organ transplantation patients. Shortly thereafter, it
was recognized that HCT recipients exhibit a shorter half-life
of MMF’s primary metabolite, mycophenolic acid (MPA)
[3,4], compared with solid organ transplantation recipients
[5]. This ﬁnding was particularly important in non-
myeloablative HCT recipients, who rely on the balance
between recipient and donor cells to ensure adequate
immunosuppression of the recipient, optimal graft-versus-
tumor effect, and minimal GVHD.
Engraftment was adequately achieved in non-
myeloablative HCT recipients of an HLA-matched related
donor graft with Q12 hr administration of oral MMF.
Engraftment proved more challenging, however, for recipi-
ents of nonmyeloablative HCT with an HLA-matcheddgments on page 1166.
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13.04.026unrelated donor graft [3]; this led to increasing the daily
MMF dose by shortening the oral MMF dosing interval from
Q12 hr to every 8 hours (Q8 hr) [6]. Engraftment rates for
patients with HLA-matched unrelated donors were further
improved with the use of granulocyte colony-stimulating
factoremobilized peripheral blood mononuclear cell
(G-PBMC) grafts instead of bone marrow grafts [3]. In
patients undergoing nonmyeloablative conditioning with an
unrelated donor graft, we demonstrated that less frequent
(Q12 hr) MMF dosing and low total MPA area under the
plasma concentration-time curve (AUC) are related to
a higher risk of graft rejection [6,7]. Low total MPA AUC is
also related to low (<50%) donor chimerism, but no signiﬁ-
cant association was observed between total or unbound
MPA AUC and acute GVHD (aGVHD) or relapse [7].
Some HCT centers personalize MMF doses based on MPA
pharmacokinetics using either trough concentration [8,9],
AUC [10], or Bayesian estimates of AUC [11]. Various inves-
tigators have reported a pharmacodynamic association
between MPA and clinical outcomes in allogeneic HCT
recipients (Supplemental Table 1) [7-9,12-14]. Many of these
studies, however, are from small patient populations (<75
patients) of adults [8,12] or children [9,13]. Studies in
a homogenous group of HCT recipients with a sufﬁcient
number of patients are essential to elucidate any MPA
pharmacodynamic associations.
In the present study, we retrospectively analyzed data
from 2 cohorts of patients receiving nonmyeloblative HCT
from a related or unrelated donor; patients received post-
grafting immunosuppression that included either Q12 hr
(n ¼ 167) or Q8 hr (n ¼ 141) MMF, and a CNI. Each cohort
Transplantation.
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concentration at steady state (Css), deﬁned as the AUC
divided by the dosing interval, and graft rejection, day 28
T-cell chimerism, grades II to IV aGVHD, relapse, nonrelapse
mortality (NRM), cytomegalovirus (CMV) reactivation, and
overall survival.
METHODS
Patient Characteristics and Treatment Plan
We retrospectively evaluated MPA pharmacodynamics in 2 separate
cohorts of patients who received nonmyeloablative HCTwith G-PBMC grafts
to treat a variety of hematological malignancies between March 1998 and
July 2006 at the Fred Hutchinson Cancer Research Center, Seattle, Wash-
ington. Given the greater risk of graft rejection among bone marrow
recipients compared with G-PBMC recipients receiving Q12 hr MMF [3],
patients who received bone marrow as the source of stem cells were
excluded.
Written informed consent was obtained from all patients before
participation in prospective treatment protocols, which included MPA
pharmacokinetic sampling. Fifty-four percent of these ambulatory clinic
patients participated in the MPA pharmacokinetic sampling. The Institu-
tional Review Board at the Fred Hutchinson Cancer Research Center
approved all study protocols, including this retrospective analysis, and an
independent Data Safety Monitoring Board monitored safety in all
prospective studies. Patient characteristics are summarized in Table 1.
The conditioning regimen comprised a single fraction of 200 to 300 cGy
total body irradiation (TBI) on day 0 with or without ﬂudarabine (30 mg/m2/
day i.v.) from day 4 to day 2 (cumulative dose 90 mg/m2) [3]. In general,Table 1
Patients’ Characteristics
Donor Type
Related
Total number 132
Sex, female/male (% female) 58/74 (44%)
HCT-CI
0 43 (33%)
1-2 35 (26%)
3-4 37 (28%)
5 15 (11%)
Not available 2 (2%)
Recipients’ ages, yr 54.5 (25.3-72.6)
Recipients’ age <21 yr 0
CMV-seropositive recipients 85 (64%)
Kahl disease risk [23]
Low 30 (23%)
Standard 66 (50%)
High 36 (27%)
Female donor-to-male recipient 42 (32%)
Donors’ age, yr 53 (17-76)
HLA-matched graft 130 (98%)
HLA-mismatched graft 2 (2%)
Year of transplantation
1998 5 (4%)
1999 21 (16%)
2000 35 (26%)
2001 23 (17%)
2002 15 (11%)
2003 0
2004 9 (7%)
2005 14 (11%)
2006 10 (8%)
Conditioning regimen
2 Gy TBI 30 (23%)
2 Gy TBI þ auto 20 (15%)
2 Gy TBI þ FLU 90 mg/m2 72 (55%)
2 Gy TBI þ FLU 90 mg/m2 þ auto 8 (6%)
3 Gy TBI þ FLU 90 mg/m2 2 (1%)
Postgrafting immunosuppression
MMF Q8 hr 0
MMF Q12 hr 132 (100%)
Cyclosporine þ MMF 104 (79%)
Tacrolimus þ MMF 28 (21%)
Auto indicates autologous (auto); FLU, ﬂudarabine monophosphate; HCT-CI, HCT c
Values are median (range) or number (%).the postgrafting CNI was either cyclosporine or tacrolimus given through
day þ177. MMF was given at 2 different dose frequencies, 15 mg/kg either
Q8 hr or Q12 hr. Adjusted ideal body weight [15] was used to determine
MMF dosing, and all doses were rounded to the nearest 250 mg. MMF doses
were not adjusted based on MPA plasma concentrations, and patients were
asked to take MMF at the same time daily. MMF treatment started on day
0 and, in general, continued until day 27 (related donor) or day 40 (unrelated
donor) at which time the MMF dose was reduced by 10% per week in the
absence of GVHD. Most donor grafts were matched for HLA-A, -B, -C, DRB1
at high-resolution DNA typing and DQB1 by intermediate-resolution tech-
niques, with the exception of 2 related and 34 unrelated donor grafts. Of the
36 patients with mismatched donor grafts, the 2 related and 22 of the 34
unrelated donor grafts had a 2 allele or antigen mismatch. The median
follow-up among patients at the time of last contact was 3.09 years (range,
.31 to 12.06 years).Pharmacokinetic Analysis
All patients had blood samples scheduled before the morning dose of
MMF and then at 1, 2, 4, 6, and 8 hours after the dose; in patients receiving
Q12 hr MMF, blood samples were also collected 10 hours after the morning
dose. Blood samples were collected in EDTA tubes, and total MPA plasma
concentrations were quantiﬁed by reverse-phase HPLC with UV detection
(adapted from Tsina et al. [16]) [7,17]. The dynamic rangewas .2 to 30 mg/mL,
and the interday coefﬁcient of variation was less than 10% [7].
Total MPA Css were evaluated on the following days: 1 Css on days
0 through 4, 246 Css on day 7 (includes days 5 through 9), 25 Css on days 10
through 18, 236 Css on day 21 (includes days 19 through 23), and 14 Css on
days 24 through 25. Unbound MPA Css were collected on the following days:
1 Css on days 0 through 4, 178 Css on day 7 (includes days 5 through 9), 18 CssUnrelated All Patients
176 308
59/117 (34%) 117/191 (38%)
44 (25%) 87 (28%)
50 (28%) 85 (28%)
57 (32%) 94 (30%)
24 (14%) 39 (13%)
1 (1%) 3 (1%)
57.8 (9.2-74.5) 55.9 (9.2-74.5)
5 (2.8%) 5 (1.6%)
105 (60%) 190 (62%)
44 (25%) 74 (24%)
80 (45%) 146 (47%)
52 (30%) 88 (29%)
40 (23%) 82 (27%)
33 (18-59) 42 (17-76)
142 (81%) 272 (88%)
34 (19%) 36 (12%)
0 5 (2%)
0 21 (7%)
21 (12%) 56 (18%)
19 (11%) 42 (14%)
28 (16%) 43 (14%)
25 (14%) 25 (8%)
37 (21%) 46 (15%)
27 (15%) 41 (13%)
19 (11%) 29 (9%)
1 (1%) 31 (10%)
0 20 (7%)
160 (91%) 232 (75%)
13 (7%) 21 (7%)
2 (1%) 4 (1%)
141 (80%) 141 (46%)
35 (20%) 167 (54%)
147 (84%) 251 (81%)
29 (16%) 57 (19%)
omorbidity index.
Table 2
Comparison of Day 7 and Day 21 Plasma MPA Pharmacokinetic Data after MMF Administration
Day 7 Day 21
Q12 hr Q8 hr Q12 hr Q8 hr
n Mean  SD (range) n Mean  SD (range) n Mean  SD (range) n Mean  SD (range)
Total MPA Css,* mg/mL 138* 2.2  .84 (.95-5.4) 108 2.9  .94 (1.1-6.9) 130 2.1  .82 (.94-4.7) 106 3.0  .99 (.61-7.0)
Unbound fraction, % 108 .94  .45 (.43-4.3) 70 1.1  .53 (.61-4.3) 99 .96  .42 (.11-3.5) 70 1.1  .43 (.59-3.0)
Unbound Css, ng/mL 108 19.6  10.4 (6.43-94.3) 70 29.5  12.8 (11.0-84.5) 99 20.2  11.4 (1.60-92.7) 70 29.8  12.7 (15.0-90.6)
* Css was calculated as AUC0-s divided by s (with s as the dosing interval). The Css term was used because of the varied administration schedules for oral MMF.
Most participants had 2 MPA Css available and are presented in this table. Of the remaining patients (not in this table), 96 had 1 total MPA Css, 2 had 3 total MPA
Css, 69 patients had no unbound MPA Css, 104 patients had 1 unbound Css, and 2 patients had 3 unbound Css (1%). Total MPA Css were evaluated on the following
days: 1 Css on day 0 through day þ4, 246 Css on day þ7 (includes days þ5 through þ9), 25 Css on days þ10 through þ18, 236 Css on day þ21 (includes days þ19
through þ23), and 14 Css on days þ24 through þ25. Unbound MPA Css were collected on the following days: 1 Css on days 0 through þ4, 178 Css on day þ7
(includes days þ5 through þ9), 18 Css on days þ10 through þ18, 169 Css on day þ21 (includes days þ19 through þ23), and 10 Css on days þ22 through þ25.
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10 Css on days 22 through 25.
Estimation of total MPA AUCs was accomplished using maximum
a posteriori probability Bayesian estimation of pharmacokinetic parameters,
incorporating a blend of individualized pharmacokinetic data and a pop-
ulation parameter prior. The maximum a posteriori probability Bayesian
method used individual patient 0- to 8-hour (Q8 hr administration) or 0- to
12-hour (Q12 hr administration) total MPA concentration-time data,
together with a pharmacokinetic model and mean parameter values plus
their variance (derived from a population pharmacokinetic analysis of 408
HCT recipients) [15]. This integrated model describes the pharmacokinetics
of total MPA AUC. The population prior parameters were not changed during
this study. The estimated total MPA Css was calculated by dividing the
Bayesian AUC estimate by the dosing interval [7], speciﬁcally AUC/12-hour
in the Q12 hr MMF group and AUC/8-hour in the Q8 hr MMF group. The
Css term was used to compare the two groups of patients because of the
varying administration schedules for oral MMF. The available MPA AUC data
from day 0 to day 25 were used to calculate the average total MPA Css term
for each patient.
The correlation between the total MPA trough concentration and MPA
Css was evaluated as well. Because of the high interoccasion (ie, within-
patient) variability of MPA absorption rate [15], the predose MPA sample
was not used as the trough concentration. The MPA trough concentration
was deﬁned as a concentration-time point collected between 7.5 and
8.5 hours postdose in patients receiving Q8 hr MMF and between 9.5 and
10.5 hours postdose in patients receiving Q12 hr MMF.
After total MPA concentrations were quantitated, the remaining plasma
over 1 AUC was pooled together to estimate the unbound fraction of MPA.
Pooling samples ensured sufﬁcient volume to be above the assay’s limit of
quantitation. Notably, the unbound fraction of MPA does not change over
a total MPA concentration range of 1 to 60 mg/mL [18]. The unbound fraction
of MPA was separated from the protein-bound MPA through equilibrium
dialysis and quantitated as previously described [7]. Speciﬁcally, 200 mL of
this pooled plasma was placed in a water-tight Teﬂon dialysis chamber
separated by dialysis membranes (Spectrapor 4; 14k molecular weight
cutoff; Spectrum Laboratories, Los Angeles, CA) and then dialyzed for
2 hours against an equal volume of 10% phosphoric acid buffer (pH 7.2) in
a water bath at 37C. After this, 120 mL dialysate was mixed with 500 mL
acetonitrile; after vortexing and drying, samples were reconstituted in
20 mM phosphate buffer (pH 3.2). The total MPA and the fraction of MPA
bound to plasma protein were quantitated, with the unbound drug
percentage calculated as follows: unbound MPA ¼ 100  (1-bound MPA).
The unbound Css were calculated by multiplying the unbound fraction of
MPA by total Css [7]. The MPA parameters evaluated for pharmacodynamic
relationships were total MPA Css, unbound MPA Css, and total MPA trough
concentration.
Toxicity
Neutropenia post-HCT was assessed only through day 28, because
multiple potential confounding variables (eg, viral infection or reactivation,
corticosteroid therapy) could affect the neutrophil count after day 28.
Neutropenia was evaluated by examining daily complete blood counts with
differential and assessment of absolute neutrophil count. CMV reactivation
was also evaluated, because it represents a signiﬁcant consequence of
immunosuppressed status; CMV serological status was assessed in each
patient and donor before HCT. All patients underwent weekly testing to
detect the CMV pp65 antigen for the ﬁrst 3 months after HCT.
Chimerism and Graft Rejection
On days 28, 56, and 84 after HCT, all patients’ peripheral blood samples
were assessed for the percentage of donor CD3þ T cells present. Flowcytometry was used to sort CD3þ cells, and chimerism was measured using
ﬂuorescence in situ hybridization and PCR of polymorphic microsatellite
regions for sex-mismatched and sex-matched grafts, respectively [19]. If
donor CD3þ cells were less than or equal to 5% at any of the assessed time
points after HCT, then the patient was noted to have graft rejection.
aGVHD, Chronic GVHD, and Disease Relapse
aGVHD and chronic GVHDwere graded according to established criteria
[20-22]. Hematological diseases were classiﬁed as low, standard, or high risk
of relapse per the Kahl criteria to evaluate relapse rate in a consistent
manner [23]. We deﬁned disease relapse or disease progression as disease
recurrence after complete remission or progression of persistent disease.
Statistical Analysis
Graphical representation of the pharmacodynamic data are shown by
the quartile of the total MPA Css, with the lower quartile (range, .61 to
1.76 mg/mL), interquartile range (1.77 to 2.96 mg/mL), and upper quartile
(range, 2.97 to 4.6 mg/mL). Cumulative incidence curves for aGVHD were
estimated using methods previously described [24]. Cox regression analysis
was used to model the effect of MPA Css on time-to-event endpoints. Death
and relapse were treated as competing risks for analysis of aGVHD and
chronic GVHD. Relapse was treated as a competing risk for the analysis of
NRM. The effects of MPA Css on hazard ratios (HRs) were expressed as the
interquartile ranges for both related and unrelated donor grafts. Mean MPA
Css were calculated up to day 25 and treated as ﬁxed covariates. Cumulative
mean MPA Css through day 25 was treated as a time-dependent covariate;
that is, at each time the covariate represented the mean of all prior
concentrations until the onset of GVHD or day 130, whichever occurred ﬁrst.
All reported P values are 2-sided, and those estimated from regression
models are derived from the Wald test. No adjustments were made for
multiple comparisons.
RESULTS
Pharmacokinetic Results
We found considerable interindividual variation of MPA
plasma concentrations in this retrospective analysis of 308
patients from whom 522 MPA AUCs were available. Most
data (506 of 522 AUCs, 97%) were collected after oral MMF
administration, with the remainder (16 of 522, 3%) collected
after i.v. MMF administration. Most patients had 2 MPA AUCs
available (67% for total MPA and 43% for unbound MPA); this
subgroup is described in detail in Table 2. Of the 522 AUCs,
376 (72%) had both total and unbound MPA AUCs available;
the remainder (146, 28%) had only total MPA AUC. Graphical
representation of the total MPA Css pharmacodynamic data
are shown by the lower quartile (range, .61 to 1.76 mg/mL),
interquartile range (1.77 to 2.96 mg/mL), and upper quartile
(range, 2.97 to 4.6 mg/mL) (Figures 1 and 2).
Because most patients had MPA Css data available on day
7 and day 21, the data from patients with an MPA Css on 1 of
those days is described in Table 2. As expected, the total and
unbound MPA Css increased with Q8 hr administration
compared with Q12 hr administration. MMF dosed based on
body weight led to considerable interpatient variability,
expressed as mean  standard deviation or fold-range
Figure 1. Association of total MPA Css with grades III to IV aGVHD (A) and NRM
(B) after day 25 in unrelated donor G-PBMC grafts. MPA Css is the average of all
values from day 0 through day 25. Total MPA Css values are lower quartile (.61
to 1.76 mg/mL), interquartile range (1.77 to 2.96 mg/mL), and upper quartile
(2.97 to 4.6 mg/mL).
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tration, there was a 5- to 5.7-fold range for total MPA Css and
14.7- to 57.9-fold range for unbound MPA Css (Supplemental
Table 2). Similarly, total MPA Css had a 6.3- to 11.4-fold range
and unbound MPA Css had a 6- to 7.7-fold range with Q8 hr
administration. Data demonstrates that limited sampling
schedules with Bayesian estimators can accurately estimate
Css [8,15]. The association of MPA pharmacokinetics with
patient characteristics is reported in a separate population
pharmacokinetic article [15]. Notably, only the concomitant
CNI, dosing weight, and albumin concentrationdbut not
conditioning regimendwere associated with total MPA
pharmacokinetics [15]. The effect of the concomitant CNI on
MPA Css is shown in Supplemental Figure 1A, B.
The association of MPA Css with the last concentration
time point obtained from pharmacokinetic sampling for Css
determination (Ctrough) was also evaluated. Studies have
established poor association between these values (R2
ranging from 3% [4] to 49% [4,7,14]), which was supported by
our own data (Supplemental Figure 1C, D). The total MPA
Ctrough was not associated with clinical outcomes
(Supplemental Table 2).
Neutropenia and CMV Reactivation
Of the 308 patients, 232 (88 related,144 unrelated) had an
absolute neutrophil count nadir below 500/mL betweendays 7 and 28. Of those 232, 53 experienced their absolute
neutrophil count nadir between days 7 and 7 and 179
between days 7 and 28. Among the 190 patients who were
CMV seropositive before HCT, 130 (68%) experienced CMV
reactivation. Speciﬁcally, 52 of 85 seropositive related (61%)
and 78 of 105 unrelated (74%) experienced CMV reactivation.
In CMV-negative recipients with a CMV-positive donor, CMV
antigenemia was detected in 4 of 12 related and 1 of 5
unrelated donor graft recipients.
Donor Chimerism and Graft Rejection
Nine of the 308 patients experienced rejection, all of
whom received MMF with cyclosporine. A detailed descrip-
tion of the patients who rejected their grafts is reported in
Table 3. One rejection occurred in a related donor graft
recipient who was conditioned with TBI only; this patient
received MMF Q12 hr with total MPA Css of 4.31 mg/mL. The
remaining 8 patients who rejected their grafts received HLA-
matched unrelated grafts after ﬂudarabine/TBI conditioning.
Of these 8 patients, 7 received an HLA-matched graft, 6
received Q12 hr MMF, and all had a total MPA Css <3 mg/mL.
Among the 36 patients who received an HLA-mismatched
graft, there was 1 case of graft rejection. The average total
MPA Css among the 36 patients receiving a mismatched graft
was 2.49 mg/mL (range, 1.1 to 3.97).
Among 308 patients, most (234, 76%) had a total MPA Css
less than 3 mg/mL. Eight of 234 patients (3.4%)with a low total
Css (<3 mg/mL) rejected their G-PBMC grafts, whereas 1 of the
74 patients (1.3%) whose Css was above 3 mg/mL had graft
rejection (P ¼ .36), as described above. Among the 234
patientswith totalMPACss less than3mg/mL,147 (62.8%)were
in the Q12 hr MMF group and 87 (37.2%) were in the Q8 hr
MMF group. Of the 141 patients receiving Q8 hr MMF, some
(38%) had an average total MPA Css greater than 3 mg/mL.
Other studies in the setting of nonmyeloablative HCT have
found that low donor T cell chimerism levels are predictive of
graft rejection [3,25,26]. Considering this, we evaluated
whether total or unbound MPA Css was associated with the
subsequent degree of day 28 donor T cell chimerism. After
adjusting for disease risk, HLA mismatch, mean week 2 CNI
concentration [27], year of transplantation [27], and female
donor-to-male recipient, there was no statistically signiﬁcant
association between mean total MPA Css and day 28 donor T
cell chimerism of 50% or lower for patients receiving related
grafts (odds ratio, .83; 95% conﬁdence interval [CI], .38 to
1.82; P ¼ .63) or unrelated grafts (odds ratio, 1.39; 95% CI, .82
to 2.37; P ¼ .23). Among the 32 patients with donor T cell
chimerism of 50% or lower, the average total MPA Css ranged
from 1.1 to 5.3 mg/mL and average unbound Css (available in
27 patients) ranged from 9.82 to 66.8 ng/mL. Graphical
representation of these data is presented in Figure 3.
Graft-versus-Host Disease
The median onset of aGVHD was day 35, with 162
patients experiencing aGVHD on or after day 25. Of these,142
patients (55 related, 87 unrelated) had grades II to IV aGVHD
and 33 (18 related, 15 unrelated) had grades III to IV aGVHD.
One hundred eleven patients with either no or grade I
aGVHD had a mean day 7 total MPA Css of 2.64 mg/mL
comparedwith amean of 2.44 mg/mL among the 190 patients
who developed grades II to IV aGVHD beyond day 7. Of those
patients with unboundMPA Css available, the mean unbound
MPA Css for the 111 patients with either no or grade I aGVHD
was 24.33 ng/mL, compared with 24.35 ng/mL for the 190
patients who developed grades II to IV aGVHD.
Figure 2. Lack of association of total MPA Css with grades III to IV aGVHD (A)
and NRM (B) after day 25 in related donor G-PBMC grafts. MPA Css is the
average of all values from days 0 through 25. Total MPA Css values are lower
quartile (.61 to 1.76 mg/mL), interquartile range (1.77 to 2.96 mg/mL), and upper
quartile (2.97 to 4.6 mg/mL).
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total MPA Css and subsequent grades III and IV GVHD for
patients receiving related grafts (HR, 1.50; 95% CI, .62 to 3.65;
P ¼ .37), as shown in Figure 2A. There was, however,
a statistically signiﬁcant association for those receiving grafts
from unrelated donors (HR, .54; 95% CI, .29 to 1.01; P ¼ .05;
Figure 1A). Grades II to IV aGVHD and chronic GVHD were
not associated with total MPA Css (Table 4) or unbound MPA
Css (Supplemental Table 3). As reﬂected in Figure 1A, patients
in the upper quartiledspeciﬁcally, those with a total MPA Css
>2.96 mg/mLdhad the lowest risk of grades III to IV aGVHD.Relapse
One hundred thirty-four patients relapsed; 63 had related
donors and 71 had unrelated donors. We found no associa-
tion between mean total MPA Css and relapse hazard for
patients with related (HR, 1.07; 95% CI, .74 to 1.55; P ¼ .73) or
unrelated donors (HR, 1.06; 95% CI, .76 to 1.47; P¼ .75). There
was no association between unbound MPA Css and relapse
for patients with related (HR,1.06; 95% CI, .77 to 1.44; P¼ .73)
or unrelated donors (HR, 1.14; 95% CI, .87 to 1.50; P ¼ .34).NRM and Overall Mortality
Ninety patients died of NRM. Of these, 35 had a related
donor and 55 had an unrelated donor. Among recipients of
a related donor graft, we found no association between totalMPA Css and risk of NRM (HR, .68; 95% CI, .35 to 1.34; P ¼ .27,
Figure 2B). For recipients of an unrelated donor graft, there
was a lower risk of NRM associated with total MPA Css (HR,
.58; 95% CI, .39 to .86; P ¼ .007). Figure 1B shows that those
patients with a total MPA Css >2.96 mg/mL had the lowest
NRM.
We found no statistically signiﬁcant relationship between
total MPA Css or unbound MPA Css and overall mortality.
Patients receiving a related graft had a hazard of overall
mortality of 1.01 (95% CI, .72 to 1.43; P¼ .96). Those receiving
an unrelated graft had a slightly lower hazard of overall
mortality; it was not, however, statistically signiﬁcant (HR,
.78; 95% CI, .61 to 1.01; P ¼ .06).
DISCUSSION
In this analysis, we evaluated MPA pharmacodynamics in
308 consecutive patients who were given nonmyeloablative
conditioning before receiving allogeneic grafts to treat
hematological malignancies. To our knowledge, this is the
largest analysis of MPA pharmacodynamics in HCT patients
to date (Supplemental Table 1). Among nonmyeloablative
HCT recipients with a related donor graft, MPA Css was not
associated with clinical outcomes (Table 4, Supplemental
Table 2). Among patients given nonmyeloablative HCT with
an unrelated donor graft, low MPA Css predicted the severity
of aGVHD (Figure 1A), which is consistent with the ﬁndings
of other investigators [12,14]. Low total MPA Css also pre-
dicted high NRM, potentially due to a higher risk of severe
GVHD. Because total MPA Css was not associated with CMV
reactivation or neutropenia (Table 4), oversuppression of the
immune system is not apparent. A few patients, however, did
not experience CMV reactivation, so it may not be possible to
observe any adverse effects from elevated MPA Css.
The initial challenge of reliable engraftment for recipients
of a nonmyeloablative HCT from an unrelated donor has been
overcome by shortening the MMF dosing interval from
Q12 hr to Q8 hr [6] and using G-PBMC grafts [3]. Low total
MPA Css has previously been related to low (<50%) T cell
donor chimerism measured on days 28, 56, and 84 [7]. The
optimal day 28 donor T cell chimerism is 50% to 90% in
nonmyeloablative HCT recipients, with chimerism >40%
associated with lower rejection risk [28]. Donor chimerism
>50% is associated with higher complete remission rates
through the graft-versus-tumor effect, which involves the
immunoreactivity of donor cells against recipient cells.
Donor chimerism <90% is associated with lower rates of
grades II to IV GVHD [26,28]. In contrast to our previous study
[7], T cell chimerism was not associated with total MPA Css
(Figure 3). In this analysis, only day 28 T cell chimerism was
evaluated because all subsequent T cell chimerism values
occur after MMF has typically been discontinued. Thus, the
day 28 T cell chimerism is the only time point at which the
MMF dose could be personalized to a target MPA Css. Addi-
tional studies regarding the association of MPA Css with
chimerism are needed, because optimizing day 28 donor T
cell chimerism could lower rates of graft rejection and GVHD
while maximizing the graft-versus-tumor effect [29].
Nevertheless, other endpoints regarding the effectiveness
of MMF are associated with total MPA Css in unrelated donor
grafts. Low total MPA Css is associated with a higher risk of
grades III to IV aGVHD (Figure 1A). We hypothesize that
personalizing the postgrafting MMF dose to achieve a target
total MPA Css could lower severe aGVHD and NRM in patients
receiving nonmyeloablative conditioning and an unrelated
donor graft. Notably, other strategiesdsuch as shortening
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C.L. McDermott et al. / Biol Blood Marrow Transplant 19 (2013) 1159e11661164the MMF dosing interval [6] or prolonged MMF administra-
tion (to day 180) and shortened cyclosporine treat-
mentdhave not decreased the incidence of GVHD among
recipients of unrelated G-PBMC grafts given non-
myeloablative conditioning [30]. To achieve higher MPA Css,
postgrafting MMF doses should be adjusted for the cova-
riates associated with MPA clearance identiﬁed in our recent
population pharmacokinetic model [15]. In a study of 408
patients, we found that total MPA clearance, adjusted for
body weight, is increased in patients receiving cyclosporine
as the concomitant CNI and in patients with lower albumin
concentrations [15]. Supplemental Figure 1, B clearly shows
that total MPA Css is lower in those patients who received
concomitant cyclosporine compared with those receiving
tacrolimus. These data support the ﬁndings by de Winter
et al. [31] that higher MPA clearance in HCT recipients is due
to higher predose cyclosporine concentrations and lower
albumin concentrations than in renal transplantation recip-
ients. All patients who experienced rejection received
concomitant cyclosporine (Table 3). Notably, MPA pharma-
cokinetic parameters are not associated with the graft source
[15]. Thus, the apparently different pharmacodynamic asso-
ciations of total MPA Css between related and unrelated
donors (Table 4) is not due to pharmacokinetic differences.
In addition to characterizing the covariates associated
with MPA pharmacokinetics, population pharmacokinetic
models can be used in conjunction with limited sampling
schedules (LSS) to estimate an individual’s MPA Css without
difﬁcult, frequent, and invasive pharmacokinetic sampling.
The creation of a population pharmacokinetic model and LSS
can greatly facilitate the identiﬁcation of pharmacodynamic
relationships [32]. Our study team observed an association
between reduced total MPA Css and higher aGVHD and NRM
after nonmyeloablative conditioning with an unrelated
donor graft. This is consistent with the ﬁndings of Jacobson
et al. [14], who reported correlations between low total MPA
trough concentrations and higher rates of graft failure and
between low unbound MPA AUC and more frequent aGVHD
in patients receiving different conditioning and grafts than
our population. In multicenter studies with an adequately
sized HCT patient population receiving a homogenous
postgrafting immunosuppressive regimen, this LSS can be
used to identify MPA pharmacodynamics associated with
clinical outcomes.
Furthermore, a population pharmacokinetic model and
LSS would facilitate personalized MMF dosing to a target
MPA Css; these approaches have been used with busulfan
[33] and cyclophosphamide [34] in HCT recipients. In the
setting of renal transplantation, MMF dose personalization
using MPA pharmacokinetics suggested lower rejection rates
and gastrointestinal toxicity [35,36]. Two of the 3 studies
used population pharmacokinetic-based LSS to personalize
oral MMF doses, reﬂecting acceptance of these tools in the
solid organ transplantation community. The target exposures
are achieved with higher oral MMF doses, and the clinical
beneﬁt of higher initial doses of oral MMF in renal trans-
plantation patients is being investigated [36]. In non-
myeloablative HCT with an unrelated donor graft, similar
prospective studies are needed in which initial oral MMF
doses are increased based on covariates associated with total
MPA pharmacokinetics. Shortening the administration
interval to every 6 hours apparently increased toxicity but
did not improve efﬁcacy in a phase I/II study of MMF with
cyclosporine as aGVHD prophylaxis in high-dose condi-
tioning recipients [4]. Therefore, increasing the initial dose
Figure 3. Lack of association between MPA Css, both total (A, B) and unbound (C, D), with day 28 donor T cell chimerism in related (A, C) and unrelated (B, D) donor
PSBC grafts. MPA Css is the average of all values from days 0 through 25.
C.L. McDermott et al. / Biol Blood Marrow Transplant 19 (2013) 1159e1166 1165while maintaining the administration interval at 8 hours
seems prudent. Notably, initial oral MMF doses would need
to bew33% higher with concomitant cyclosporine to achieve
a similar total MPA Css to that achieved with oral MMF with
concomitant tacrolimus, because cyclosporine coadminis-
tration increases total MPA clearance by 33.8% [15]. Also,Table 4
Effect of Increasing Mean Total MPA Css as Fixed Covariate on Clinical
Outcomes Occurring after Day 25*
Donor Type
Related (n ¼ 132) Unrelated (n ¼ 176)
Odds Ratio/HR
(95% CI)
P Odds Ratio/HR
(95% CI)
P
Day 28 T cell
chimerism <50%
.83 (.38-1.82) .63 1.39 (.82-2.37) .23
Acute GVHD II-IV .86 (.56-1.32) .48 .79 (.59-1.07) .13
Acute GVHD III-IV 1.50 (.62-3.65) .37 .54 (.29-1.01) .05
Chronic GVHD .68 (.47-.99) .04 .97 (.75-1.27) .84
Relapse 1.07 (.74-1.55) .73 1.06 (.76-1.47) .75
Neutrophil nadir 1.53 (.90-2.61) .12 .87 (.62-1.24) .45
CMV reactivation 1.00 (.63-1.59) .99 .88 (.64-1.19) .40
Nonrelapse mortality .68 (.35-1.34) .27 .58 (.39-.86) .007
Overall mortality 1.01 (.72-1.43) .96 .78 (.61-1.01) .06
* MPA Css ﬁt as continuous variable (truncated at 97.5th percentile to
avoid outliers); HR per unit of MPA Css (mg/mL), adjusted for Kahl disease
risk, antigen/2-allele mismatch, mean CNI concentration during week 2,
year of transplant, female donor-to-male patient, tacrolimus prophylaxis,
and ﬂudarabine in conditioning (related donors only). Mean CNI week 2 ﬁt
as continuous variable, rescaled as standard deviation units to account for
difference between cyclosporine and tacrolimus concentrations.increased total MPA clearance is associated with decreasing
albumin concentration; thus, those patients with low
albumin would need higher initial oral MMF doses. Further
studies, in which oral MMF doses are personalized using
a population pharmacokinetic-based LSS, are also needed.
The only pharmacodynamic association between total
MPA Css and outcomes was observed in patients receiving an
unrelated donor graft. In patients receiving a related donor
graft, future studies should seek to evaluate additional
biomarkers, such as inosine monophosphate dehydrogenase
(IMPDH) activity. MPA selectively and reversibly inhibits
IMPDH activity, which has been associated with rejection in
renal transplantation patients [37]. The feasibility of evalu-
ating IMPDH activity in HCT recipients has been established
[38]. IMPDH activity may be an important biomarker,
because it is inﬂuenced by MPA concentrations and an
individual patient’s sensitivity to IMPDH inhibition by MPA.
In conclusion, we found that low total MPA Css was asso-
ciated with an increased risk of grades III to IV aGVHD and
NRM in recipients of unrelated donor grafts after non-
myeloablative conditioning. These ﬁndingswere not observed
in patients receiving a related donor graft. Studies are
needed to identify alternative biomarkersdsuch as IMPDH
activitydin these patients. Future prospective trials should
address the clinical beneﬁt of higher initial oral MMF dos-
esdpersonalized based on covariatesdand/or personalizing
oral MMF doses to a targetMPA Css above 2.96 mg/mL to lower
aGVHD and NRM rates in unrelated donor patients receiving
nonmyeloablative conditioning.
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